109 related articles for article (PubMed ID: 31974710)
1. Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.
Hudson L; Gower N; Lenarcic S; Trufan SJ; White RL
Ann Surg Oncol; 2020 Jul; 27(7):2248-2254. PubMed ID: 31974710
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
[TBL] [Abstract][Full Text] [Related]
4. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tasks of breast MRI surveillance for high-risk women with cancer susceptibility genes other than BRCA1/2: a single institution study.
Kikuchi M; Gomi N; Ueki A; Osako T; Terauchi T
Breast Cancer; 2023 Jul; 30(4):577-583. PubMed ID: 36897545
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
7. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
[TBL] [Abstract][Full Text] [Related]
8. Frequency of Pathogenic Germline Variants in
Petridis C; Arora I; Shah V; Moss CL; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1162-1168. PubMed ID: 31263054
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Pathogenic Germline Mutations in 13 Hereditary Cancer-Related Genes in Breast Cancer Patients in Narathiwat Province, Thailand.
Sukpan P; Kanokwiroon K; Sriplung H; Laochareonsuk W; Choochuen P; Auseng N; Wanawanakorn K; Sangkhathat S
Asian Pac J Cancer Prev; 2023 Feb; 24(2):525-530. PubMed ID: 36853301
[TBL] [Abstract][Full Text] [Related]
11. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
12. Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
Wood ME; McKinnon W; Garber J
Breast J; 2020 Aug; 26(8):1528-1534. PubMed ID: 32741080
[TBL] [Abstract][Full Text] [Related]
13. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
[TBL] [Abstract][Full Text] [Related]
15. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system.
Knerr S; Guo B; Wernli KJ; Mittendorf KF; Feigelson HS; Gilmore MJ; Jarvik GP; Kauffman TL; Keast E; Liles EG; Lynch FL; Muessig KR; Okuyama S; Veenstra DL; Zepp JM; Wilfond BS; Devine B; Goddard KAB
Breast Cancer Res Treat; 2023 Oct; 201(3):461-470. PubMed ID: 37470892
[TBL] [Abstract][Full Text] [Related]
19. Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing.
Rosenthal ET; Evans B; Kidd J; Brown K; Gorringe H; van Orman M; Manley S
J Am Coll Radiol; 2017 Apr; 14(4):561-568. PubMed ID: 28011157
[TBL] [Abstract][Full Text] [Related]
20. Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians.
Han MR; Zheng W; Cai Q; Gao YT; Zheng Y; Bolla MK; Michailidou K; Dennis J; Wang Q; Dunning AM; Brennan P; Chen ST; Choi JY; Hartman M; Ito H; Lophatananon A; Matsuo K; Miao H; Muir K; Sangrajrang S; Shen CY; Teo SH; Tseng CC; Wu AH; Yip CH; Kang D; Xiang YB; Easton DF; Shu XO; Long J
Carcinogenesis; 2017 May; 38(5):511-518. PubMed ID: 28419251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
